Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13458MR)

This product GTTS-WQ13458MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2&TNFRSF9 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001005862.3; NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 3604
UniProt ID P04626; Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13458MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5004MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ1668MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ8859MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ2131MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ15707MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ7512MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ14929MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1708MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW